Johnson & Johnson's Janssen Submits Marketing Authorization Application To EMA Seeking Approval Of Single Tablet Combination Therapy Of Macitentan And Tadalafil For Treatment Of Patients With Pulmonary Arterial Hypertension
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's Janssen has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) seeking approval for a single tablet combination therapy of Macitentan and Tadalafil for the treatment of patients with Pulmonary Arterial Hypertension.
June 26, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
J&J's Janssen submits application to EMA for approval of a single tablet combination therapy for Pulmonary Arterial Hypertension treatment.
The submission of the Marketing Authorization Application to the EMA is a positive step for Johnson & Johnson's Janssen, as it seeks to expand its product portfolio and potentially increase revenues. If approved, the new treatment could provide growth opportunities for the company in the Pulmonary Arterial Hypertension market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100